Sensus Healthcare, Inc. (SRTS)
NASDAQ:SRTS
Top Page
Sensus Healthcare
(NASDAQ:SRTS)
Select Model
Select Model
Rating:52Neutral
Price Target:
$4.50
▲(27.84% Upside)
Action:ReiteratedDate:03/05/26
The score is held back primarily by weak and volatile 2025 financial performance (revenue decline, margin compression, and losses) and a negative earnings-based valuation (negative P/E). Offsetting factors include a very strong, low-debt balance sheet and a more optimistic earnings-call outlook tied to new CPT reimbursement codes and guidance for sequential improvement and a 2026 profitability target, while technical indicators remain broadly neutral.
Positive Factors
Reimbursement clarity (CPT codes)
Dedicated CPT codes create a structural reimbursement uplift (management cited ~300% per-fraction increase). Lasting reimbursement clarity improves physician economics, shortens purchase payback, underpins sustained demand and utilization, and materially reduces payor uncertainty over the 2–6 month commercialization horizon.
Negative Factors
Revenue and margin deterioration
A sharp revenue decline and swing to a sizable net loss indicate structural volatility in demand, pricing or customer mix. Such deterioration undermines margin sustainability and the ability to generate reliable operating cash, creating risk that near-term profitability targets may be difficult to achieve without durable demand recovery.
Read all positive and negative factors
Positive Factors
Negative Factors
Reimbursement clarity (CPT codes)
Dedicated CPT codes create a structural reimbursement uplift (management cited ~300% per-fraction increase). Lasting reimbursement clarity improves physician economics, shortens purchase payback, underpins sustained demand and utilization, and materially reduces payor uncertainty over the 2–6 month commercialization horizon.
Read all positive factors
Sensus Healthcare (SRTS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$73.91M
Dividend YieldN/A
Average Volume (3M)59.47K
Price to Earnings (P/E)―
Beta (1Y)0.92
Revenue Growth-13.79%
EPS Growth-132.21%
CountryUS
Employees54
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.19
Shares Outstanding16,462,059
10 Day Avg. Volume35,212
30 Day Avg. Volume59,470
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.35
Price to Sales (P/S)2.36
P/FCF Ratio195.73
Enterprise Value/Market Cap0.71
Enterprise Value/Revenue1.91
Enterprise Value/Gross Profit4.42
Enterprise Value/Ebitda-7.83
Forecast
1Y Price Target
$6.50Price Target Upside84.66% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.28
Revenue Forecast (FY)$27.97M
Sensus Healthcare Business Overview & Revenue Model
Company Description
Sensus Healthcare, Inc., a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy (SRT), a low-energy X-ray technology in its portfolio of treatmen...
How the Company Makes Money
Sensus Healthcare generates revenue through the sale of its medical devices and systems, specifically the Sensus system, which is used for non-invasive skin cancer treatment. The company's revenue model is primarily based on direct sales to health...
Sensus Healthcare Key Performance Indicators (KPIs)
Sensus Healthcare Earnings Call Summary
Earnings Call Date:Feb 12, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:Apr 30, 2026
Earnings Call Sentiment Neutral
The call presented a mixed picture: near-term financial results for 2025 showed significant deterioration (large YoY revenue declines, margin compression, and swings to net losses and negative adjusted EBITDA), while the company highlighted a material strategic inflection—CMS granting dedicated CPT codes, a clean balance sheet ($22.1M cash, zero debt), accelerating utilization under the FDA fair deal program, international demand, and a commercial scaling plan. Management is positioning 2026 as a transition year with expectations for sequential Q1 improvement and a goal of full-year profitability, but materially adverse 2025 results and uncertainty around the lost volume from the largest customer temper the outlook.Positive Updates
New Dedicated CPT Codes for SRT and IGSRT
CMS awarded exclusive and dedicated CPT codes for SRT and IGSRT effective 01/01/2026, creating clear reimbursement for nonmelanoma skin cancer treatments and management commentary indicating a ~300% per-fraction reimbursement increase cited on the call.
Negative Updates
Sharp Decline in Quarterly Revenue
Q4 2025 revenue was $4.9M versus $31.0M in Q4 2024, a decline of approximately -84.2% year-over-year, driven primarily by a lower number of units sold and reduced sales to the company's largest customer.
Read all updates
Q4-2025 Updates
Positive
Negative
New Dedicated CPT Codes for SRT and IGSRT
CMS awarded exclusive and dedicated CPT codes for SRT and IGSRT effective 01/01/2026, creating clear reimbursement for nonmelanoma skin cancer treatments and management commentary indicating a ~300% per-fraction reimbursement increase cited on the call.
Read all positive updates
Company Guidance
Management guided that Q1 2026 system shipments should exceed Q4’s 14 units and Q1 revenues should exceed Q4’s $4.9M, and the company is targeting full‑year profitability in 2026 (guidance excludes any contribution from its historically largest customer). They plan to scale the sales force (one rep added; 3–5 additional hires planned in Q1), continue the fair‑deal program (18 active FDA sites, 10 pending) after 2025 treatments rose >8x and patients treated increased >250%, and expect growing international demand (six international units shipped in Q4). Management pointed to new CPT codes effective 1/1/2026 (cited ~300% per‑fraction increase), a clean balance sheet with $22.1M cash and zero debt, inventories of $14.6M (prepaids $1.5M), and said these factors should drive higher utilization and profitability despite FY2025 revenue of $27.5M and a FY2025 net loss of $7.7M (‑$0.47/sh) and Q4 net loss of $3.2M (‑$0.19/sh).Sensus Healthcare Financial Statement Overview
Summary
Income Statement
38
Negative
Balance Sheet
82
Very Positive
Cash Flow
44
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 27.48M | 41.81M | 24.41M | 44.53M | 27.04M |
| Gross Profit | 11.87M | 24.43M | 14.06M | 29.63M | 16.99M |
| EBITDA | -9.92M | 8.52M | 79.00K | 15.34M | 4.73M |
| Net Income | -7.72M | 6.65M | 485.00K | 24.24M | 4.12M |
Balance Sheet | |||||
| Total Assets | 53.04M | 62.16M | 53.71M | 56.73M | 32.24M |
| Cash, Cash Equivalents and Short-Term Investments | 22.08M | 22.06M | 23.15M | 25.52M | 14.52M |
| Total Debt | 680.00K | 602.00K | 783.00K | 1.02M | 225.00K |
| Total Liabilities | 4.94M | 6.34M | 4.87M | 8.67M | 6.22M |
| Stockholders Equity | 48.10M | 55.83M | 48.84M | 48.07M | 26.02M |
Cash Flow | |||||
| Free Cash Flow | 332.00K | -1.11M | -2.37M | -1.57M | -414.00K |
| Operating Cash Flow | 528.00K | -831.00K | -2.15M | -1.41M | -286.00K |
| Investing Cash Flow | -196.00K | -276.00K | -187.00K | 14.84M | 129.00K |
| Financing Cash Flow | -305.00K | 15.00K | -40.00K | -2.43M | -231.00K |
Sensus Healthcare Technical Analysis
Positive
3.52
Price Trends
4.29
Positive
4.27
Positive
4.04
Positive
Market Momentum
0.06
Negative
59.83
Neutral
88.54
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SRTS, the sentiment is Positive. The current price of 3.52 is below the 20-day moving average (MA) of 4.09, below the 50-day MA of 4.29, and below the 200-day MA of 4.04, indicating a bullish trend. The MACD of 0.06 indicates Negative momentum. The RSI at 59.83 is Neutral, neither overbought nor oversold. The STOCH value of 88.54 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SRTS.
Sensus Healthcare Risk Analysis
Sensus Healthcare disclosed 24 risk factors in its most recent earnings report. Sensus Healthcare reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Sensus Healthcare Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $118.53M | -2.59 | -103.93% | ― | -20.10% | 7.87% | |
52 Neutral | $73.91M | -5.13 | -15.11% | ― | -13.79% | -132.21% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $60.37M | -2.68 | -116.22% | ― | 14.04% | -0.65% | |
46 Neutral | $22.21M | -2.58 | -221.04% | ― | -18.96% | 8.98% | |
44 Neutral | $37.93M | -4.85 | -91.54% | ― | -8.97% | 47.29% | |
39 Underperform | $4.99M | -0.35 | -247.60% | ― | ― | 15.03% |
* Healthcare Sector Average
SRTS
Sensus Healthcare
4.49
-0.30
-6.26%
NSPR
InspireMD
1.29
-1.31
-50.38%
CTSO
Cytosorbents
0.61
-0.38
-38.38%
RBOT
Vicarious Surgical
0.70
-4.70
-87.04%
HYPR
Hyperfine
1.21
0.47
64.40%
ICCM
Icecure Medical
0.32
-0.82
-71.67%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.